Investors / France / Sofinnova Partners
Sofinnova Partners
Venture capital · France · Europe
Sofinnova Partners is a life sciences venture capital firm founded in 1972 that invests across the life sciences value chain, from seed to later-stage. It operates a multi-fund platform of investment strategies with dedicated teams, including biopharma, medtech, industrial biotech, digital medicine and accelerator strategies.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechmedtechhealthtechindustrial biotechsustainability
Your fit with Sofinnova Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsSofinnova Partners lists 114 checked portfolio companies on its own site and is named in 26 funding rounds, 13 of them as lead. Its most frequent entry is Series A, 33% of the companies with a known first round. Its largest themes are Healthcare & Biotech (69%), AI & Machine Learning (13%) and Food & Agriculture (4%). 34% of its companies are based in United States. It invests most often alongside MD Start, Agoranov and Indaco Venture Partners SGR.
Counts come from funding rounds that name Sofinnova Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Sofinnova Partners' whole history. Rounds on record name 26 companies; its own site lists 114. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 17% |
| Series A | 33% |
| Series B | 17% |
| Growth | 33% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 1 |
| '25 | 9 | 4 |
| '26 | 16 | 8 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 96th | 111 companies |
| Recent activity | 98th | 17 rounds in 12 months |
| Early stage | 57th | 17% of entries at pre-seed or seed |
| Evidence | 91th | 20% of companies confirmed by a round |
| Sector focus | 91th | 69% in its largest sector |
| Reach | 99th | 16 countries |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 69% | 15% |
| AI & Machine Learning | 13% | 18% |
| Food & Agriculture | 4% | 3% |
| Industrial & Manufacturing | 4% | 7% |
| Space & Defense | 4% | 3% |
| Media & Entertainment | 2% | 4% |
| Legal & Compliance | 2% | 2% |
| Consumer | 2% | 3% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| MD Start | 9 |
| Agoranov | 6 |
| Indaco Venture Partners SGR | 6 |
| RA Capital | 6 |
| Sanofi Ventures | 4 |
| Aisling Capital | 3 |
| Asabys Partners | 3 |
| Astellas Venture Management | 3 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers10693%
- No longer answers00%
- Points to another company87%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherCompare Sofinnova Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Sofinnova Partners| Date | Company | Stage |
|---|---|---|
| 5 Nov 2026 | Series B | |
| 5 Nov 2026 | Series A Led | |
| 26 Oct 2026 | Series C+ Led | |
| 20 Oct 2026 | Seed Led | |
| 22 Sept 2026 | Series C+ | |
| 22 Sept 2026 | Series C+ Led | |
| 5 Aug 2026 | Series B | |
| 22 Jun 2026 | Series A Led |
Round details for Sofinnova Partners
Amounts, full round histories and every co-investor in Sofinnova Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
114 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
Healthcare & Biotech | Portfolio page | |||
| Abivax is a clinical-stage biopharmaceutical company developing obefazimod, an oral small molecule that enhances miR-124 expression, for the treatment of inflammatory diseases such as ulcerative colitis and Crohn's disease. | Healthcare & BiotechMedia & Entertainment | Portfolio page | ||
| Actithera develops innovative radiotherapeutics by linking radioactive isotopes to carefully designed molecules to fight cancer. | Healthcare & Biotech | Portfolio page | ||
| Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. | Healthcare & Biotech | Portfolio page | ||
| Afyren produces biosourced molecules to replace petroleum-derived molecules in various products. | Industrial & ManufacturingSpace & Defense | Portfolio page | ||
| Alethio Therapeutics is developing therapies to improve outcomes for patients with myeloproliferative neoplasms, a group of blood cancers. | Healthcare & Biotech | Nov 2026Series A | Page + round | |
| Alia Therapeutics is a gene editing company that develops treatments for genetic diseases. | Healthcare & Biotech | Portfolio page | ||
| Arzeda designs proteins for various applications, including sweeteners, home care, advanced materials, and biologics. | Healthcare & BiotechFood & Agriculture | Portfolio page | ||
| Ascendis Pharma is a biopharmaceutical company that develops new therapies using its TransCon technology platform to improve treatment safety, efficacy, tolerability, and convenience. | Healthcare & Biotech | Portfolio page | ||
| Asceneuron discovers and develops therapeutics for neurodegenerative disorders | Healthcare & Biotech | Portfolio page | ||
| Avantium develops sustainable chemistry solutions and plant-based plastics. | Space & DefenseSpace & Defense | Portfolio page | ||
| BioCorteX develops and runs in-silico bridge trials to determine how pharmaceuticals interact with bacteria in different populations | Healthcare & Biotech | Portfolio page | ||
| Bionyra Pharma is a clinical-stage biopharmaceutical company developing antibody therapies for immune-mediated inflammatory diseases such as atopic dermatitis and inflammatory bowel disease. | Healthcare & Biotech | Jun 2026Series A | Page + round | |
| Bioptimus trains foundation models to learn the dynamics of human biology and predict outcomes | Healthcare & Biotech | Portfolio page | ||
| Biosyntia produces nutrition and health products using natural ingredients and unique technology. | Healthcare & Biotech | Portfolio page | ||
| Biotalys develops protein-based biocontrol solutions for crop protection | AI & Machine LearningAI & Machine Learning | Portfolio page | ||
| BiovelocITA is a biotech accelerator that develops early-stage therapeutic projects into biotechnology companies. | Healthcare & BiotechFintech | Portfolio page | ||
| Borea Therapeutics develops gene therapies using chemically modified adeno-associated virus (AAV) vectors based on a click chemistry platform. | Healthcare & Biotech | Portfolio page | ||
| Calliditas Therapeutics develops and commercializes novel medications for rare diseases, including renal and hepatic diseases. | Healthcare & Biotech | Portfolio page | ||
| Catamaran Bio engineers NK cell therapies to provide treatments for solid tumors and other cancers. | Healthcare & Biotech | Portfolio page |
About this data
site last read 11 Nov 2026- Site
- sofinnovapartners.com
- Last read
- 11 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Jan 2024
- Companies checked
- 114
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Sofinnova Partners' profile as data
Pull Sofinnova Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/sofinnovapartners.com
# also
GET /v1/firms/sofinnovapartners.com/portfolio
GET /v1/firms/sofinnovapartners.com/coinvestors
GET /v1/firms/sofinnovapartners.com/news